Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953163 | 0.85 | IMPDH2 (0.37) | ALDH1A1CYP1A2 | |
| SCHEMBL9952242 | 0.84 | IMPDH2 (0.36) | LMNAHTTALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL14742267 | 0.81 | LMNA (0.34) | LMNAHTTALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL9953070 | 0.79 | HTR2A (0.39) | LMNAHTTCYP1A2 | |
| SCHEMBL9952103 | 0.75 | ERN1 (0.30) | — | |
| SCHEMBL9953841 | 0.75 | LMNA (0.39) | LMNAHTTALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL9929183 | 0.73 | CYP3A4 (0.41) | LMNAHTTALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL18038554 | 0.73 | LMNA (0.38) | LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL28114021 | 0.72 | LMNA (0.38) | LMNAHTTALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL20254981 | 0.72 | PDE2A (0.36) | LMNAHTTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158891-A1 | SALTS AND SOLID FORMS AND PROCESSES OF PREPARING A PI3K INHIBITOR | INCYTE CORPORATION (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3801533-A1 | DOSING REGIMEN FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3262046-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | Incyte Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138363-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | INCYTE CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-2961410-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |